Merck is closing in on a deal to buy Cidara Therapeutics in a deal valuing the biotechnology company at a premium to its $3.3 billion market capitalization, the Financial Times reported on Thursday. The deal could be...
Shah Capital pushes for Novavax sale, warns of proxy fight
Shah Capital, Novavax’s second-largest shareholder, is pressing the biotech’s board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is made in...
Pfizer to acquire obesity drug startup Metsera in $10 billion deal
Obesity drug developer Metsera said Friday that it had agreed to a deal to be acquired by Pfizer, which had been locked in a bidding war for the company with Novo Nordisk, the Danish maker of weight-loss treatments...
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle
Obesity drug developer Metsera said on Friday that it accepted Pfizer’s $10 billion acquisition offer, in what could be the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that...
Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera
Pfizer and Novo Nordisk’s fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted sweetened bids, with Metsera saying Novo’s $10 billion offer is superior. The dramatic...
Cipla to fully acquire Inzpera Healthscience
Drug maker Cipla on Monday said it has inked a pact to fully acquire Inzpera Healthscience for around Rs 111 crore. The drug maker has entered into definitive agreements to acquire 100 per cent stake in Inzpera...
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on Tuesday. Novo’s revised offer brings the deal value to about $10 billion, while Pfizer is now willing to shell out $8...
Novartis to acquire Avidity Biosciences for about $12 billion
Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders. As...
CCI clears Torrent Pharma’s proposal to buy stake in JB Chemicals
Fair trade regulator CCI on Tuesday cleared Torrent Pharmaceuticals Ltd’s proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications offered by the companies. The...
Natco Pharma to acquire significant stake in S African firm Adcock Ingram
India’s Natco Pharma will acquire significant stakes in 135-year-old South African pharmaceutical giant Adcock Ingram. The R 4.2-billion deal will see Adcock Ingram becoming a privately-held entity co-owned by...
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push
Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic...
Life sciences companies may turn to spin-offs to avoid sell-offs
Big Pharma continues its hunt for innovation, and with uncertain market and regulatory conditions, some life sciences companies may be feeling the pressure to make their M&A exit or need additional funding in this...
